Comparison of real-world direct healthcare costs for metastatic colorectal cancer patients treated with cetuximab vs. bevacizumab as first-line therapy.

Cancer Patients ◽

Real World ◽

Healthcare Costs ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Direct Healthcare Costs ◽

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component

Cancer Medicine ◽

10.1002/cam4.3876 ◽

2021 ◽

Author(s):

Yu‐Wen Zhou ◽

Yi‐Xiu Long ◽

Ye Chen ◽

Ji‐Yan Liu ◽

Dan Pu ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Mucinous Adenocarcinoma ◽

First Line ◽

First Line Therapy ◽

Mucinous Component ◽

Line Therapy ◽

1228 Real-world direct healthcare costs for metastatic colorectal cancer patients treated with cetuximab vs. bevacizumab containing regimen in first-line, or sequentially in first- and second-line, from a US private payer perspective

European Journal of Cancer ◽

10.1016/s0959-8049(16)30532-9 ◽

2015 ◽

Vol 51 ◽

pp. S182

Author(s):

S. Johnston ◽

K. Wilson ◽

E. Riehle ◽

H. Varker ◽

P. Juneau ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Real World ◽

Healthcare Costs ◽

Second Line ◽

First Line ◽

Payer Perspective ◽

Direct Healthcare Costs ◽

Colorectal Cancer Patients ◽

Private Payer

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Annals of Oncology ◽

10.1093/annonc/mdy281.038 ◽

2018 ◽

Vol 29 ◽

pp. viii165

Author(s):

T. Buchler ◽

O. Fiala ◽

V. Veskrnova ◽

R. Chloupkova ◽

A. Poprach ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Cancer Patients ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

Targeted Oncology ◽

10.1007/s11523-018-0597-7 ◽

2018 ◽

Vol 13 (6) ◽

pp. 735-743 ◽

Cited By ~ 2

Author(s):

Ondrej Fiala ◽

Veronika Veskrnova ◽

Renata Chloupkova ◽

Alexandr Poprach ◽

Igor Kiss ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Cancer Patients ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery

Current Colorectal Cancer Reports ◽

10.1007/s11888-015-0259-4 ◽

2015 ◽

Vol 11 (2) ◽

pp. 54-69

Author(s):

Andre M. Murad ◽

Lucas S. Murad

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

First Line ◽

Curative Surgery ◽

First Line Therapy ◽

Line Therapy ◽

P-89 Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy

Annals of Oncology ◽

10.1016/j.annonc.2020.04.171 ◽

2020 ◽

Vol 31 ◽

pp. S118-S119

Author(s):

M. Pérez Martelo ◽

J. Álvarez Fernández ◽

I. Abdulkader Nallib ◽

E. Brozos Vázquez ◽

F. Vázquez Rivera ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Prognostic Significance ◽

Population Based ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Capecitabine plus bevacizumab as first-line therapy for metastatic colorectal cancer patients with poor performance status

Journal of Nippon Medical School ◽

10.1272/jnms.jnms.2021_88-415 ◽

2020 ◽

Author(s):

Yasufumi Yamada ◽

Kazuhiko Yoshimatsu ◽

Hajime Yokomizo ◽

Sachiyo Okayama ◽

Masaya Satake ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Performance Status ◽

Poor Performance ◽

Poor Performance Status ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

PD-0015 Influence of BRAF V600E and Different Kras Mutations on Outcome of Metastatic Colorectal Cancer Patients Treated with First- Line Therapy

Annals of Oncology ◽

10.1016/s0923-7534(19)66509-9 ◽

2012 ◽

Vol 23 ◽

pp. iv24

Author(s):

Martina Rebersek ◽

Marko Boc ◽

Zvezdana Hlebanja ◽

Neva Volk ◽

Jernej Benedik ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Braf V600e ◽

First Line ◽

Kras Mutations ◽

First Line Therapy ◽

Line Therapy ◽

The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy

Tumor Biology ◽

10.1007/s13277-014-2693-3 ◽

2014 ◽

Vol 36 (3) ◽

pp. 1519-1527 ◽

Cited By ~ 12

Author(s):

M. Tampellini ◽

A. Ottone ◽

I. Alabiso ◽

C. Baratelli ◽

L. Forti ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Advanced Colorectal Cancer ◽

Time Dependent ◽

Prognostic Role ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data

PharmacoEconomics ◽

10.1007/s40273-020-00951-1 ◽

2020 ◽

Vol 38 (11) ◽

pp. 1263-1275

Author(s):

Koen Degeling ◽

Hui-Li Wong ◽

Hendrik Koffijberg ◽

Azim Jalali ◽

Jeremy Shapiro ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Real World ◽

Registry Data ◽

First Line ◽

Colorectal Cancer Patients ◽

Doublet Chemotherapy